Abstract
Human induced pluripotent stem cells (hiPSCs) have great potential as a robust source of progenitors for regenerative medicine. The novel technology also enables the derivation of patient-specific cells for applications to personalized medicine, such as for personal drug screening and toxicology. However, the biological characteristics of iPSCs are not yet fully understood and their similarity to human embryonic stem cells (hESCs) is still unresolved. Variations among iPSCs, resulting from their original tissue or cell source, and from the experimental protocols used for their derivation, significantly affect epigenetic properties and differentiation potential. Here we review the potential of iPSCs for regenerative and personalized medicine, and assess their expression pattern, epigenetic memory and differentiation capabilities in relation to their parental tissue source. We also summarize the patient-specific iPSCs that have been derived for applications in biological research and drug discovery; and review risks that must be overcome in order to use iPSC technology for clinical applications.
Keywords: Differentiation, epigenetic memory, hES cells, iPS cells, personalized medicine, regenerative medicine, reprogramming.
Current Molecular Medicine
Title:Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Volume: 13 Issue: 5
Author(s): R. Shtrichman, I. Germanguz and J. Itskovitz- Eldor
Affiliation:
Keywords: Differentiation, epigenetic memory, hES cells, iPS cells, personalized medicine, regenerative medicine, reprogramming.
Abstract: Human induced pluripotent stem cells (hiPSCs) have great potential as a robust source of progenitors for regenerative medicine. The novel technology also enables the derivation of patient-specific cells for applications to personalized medicine, such as for personal drug screening and toxicology. However, the biological characteristics of iPSCs are not yet fully understood and their similarity to human embryonic stem cells (hESCs) is still unresolved. Variations among iPSCs, resulting from their original tissue or cell source, and from the experimental protocols used for their derivation, significantly affect epigenetic properties and differentiation potential. Here we review the potential of iPSCs for regenerative and personalized medicine, and assess their expression pattern, epigenetic memory and differentiation capabilities in relation to their parental tissue source. We also summarize the patient-specific iPSCs that have been derived for applications in biological research and drug discovery; and review risks that must be overcome in order to use iPSC technology for clinical applications.
Export Options
About this article
Cite this article as:
Shtrichman R., Germanguz I. and Eldor J. Itskovitz-, Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine, Current Molecular Medicine 2013; 13 (5) . https://dx.doi.org/10.2174/1566524011313050010
DOI https://dx.doi.org/10.2174/1566524011313050010 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome
Current Cardiology Reviews Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry [General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry Conjugation of Resveratrol with RGD and KGD Derivatives
Protein & Peptide Letters Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde
Current Cancer Drug Targets Development of New Drugs for COPD
Current Medicinal Chemistry Cardiac Dysfunction in Rats with Dietary-Induced Insulin Resistance Associated with Pharmacologically-induced Dyslipidemia
Current Pharmaceutical Design Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Molecular Mechanisms of the Antiatherogenic Action of Adiponectin
Vascular Disease Prevention (Discontinued) Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Current Vascular Pharmacology Socioeconomic Position and Type 2 Diabetes Mellitus in Europe 1999- 2009: a Panorama of Inequalities
Current Diabetes Reviews Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Is There any Correlation Between Diabetic Retinopathy and Risk of Cardiovascular Disease?
Current Diabetes Reviews Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry